Caplacizumab Without Plasma Exchange for Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness

Am J Ther. 2023 Sep-Oct;30(5):e502-e505. doi: 10.1097/MJT.0000000000001522. Epub 2022 May 26.

Authors

Caleb Spencer¹, Ziad Abuhelwa¹, Azizullah Beran¹, Anas Alsughayer¹, Taha Sheikh², Drew Oostra², Ragheb Assaly^{1

3}, Danae M Hamouda²

Affiliations

¹ Department of Medicine, University of Toledo, Toledo, OH.
² Division of Hematology and Oncology, Department of Medicine, University of Toledo, Toledo, OH.
³ Division of Pulmonology and Critical Care Medicine, Department of Medicine, University of Toledo, Toledo, OH.

PMID: 37713712
DOI: 10.1097/MJT.0000000000001522

No abstract available

MeSH terms

ADAMTS13 Protein
Humans
Jehovah's Witnesses*
Plasma Exchange
Purpura, Thrombotic Thrombocytopenic* / drug therapy
Single-Domain Antibodies* / therapeutic use

Substances

caplacizumab
Single-Domain Antibodies
ADAMTS13 Protein